CRH Medical announces anticipated revenue for the year ending December 31, 2012

VANCOUVER, Jan. 15, 2013 /CNW/ - CRH Medical Corporation (TSX: CRH), (OTCQX: CRMMF), a North American medical company focused on providing physicians with innovative products for the treatment of gastrointestinal diseases, today announced that it expects to report revenue for the year ended December 31, 2012 of approximately US$6,850,000.

The anticipated revenue for the year ending December 31, 2012 would represent a 24% increase compared to the year ending December 31, 2011. This announced revenue is a preliminary, unaudited management assessment of revenue for the period.

As of December 31, 2012, the Company has trained 1,332 physicians to use the O'Regan System, representing 451 clinical practices. This compares to 1,054 physicians trained, representing 341 clinical practices, as of December 31, 2011.

"During 2012, we continued the implementation of our business strategy to train physicians to utilize the CRH O'Regan system so that they can provide their patients with a highly effective and safe treatment for hemorrhoids," said Edward Wright, Chief Executive Officer of CRH Medical. "Additionally, in late 2012, we introduced a Clinical Sales Support Program designed to accelerate the Company's long-term revenue growth and profitability. By mid 2013, we should be in a position to evaluate the effectiveness of the pilot program."

The O'Regan System is a single use, disposable, hemorrhoid treatment that is safe and highly effective in treating hemorrhoid grades I - IV.  The Company's goal is to establish the O'Regan System as the standard of care for hemorrhoid treatment. In addition to the product, CRH Medical delivers clinical, marketing and operational support directly to its partner physicians.

CRH Medical intends to announce comprehensive 2012 year-end audited results by March 31, 2013.

About CRH Medical Corporation:

CRH Medical Corporation specializes in the distribution of innovative medical products directly to physicians, particularly those in the gastroenterologist community. The Company's lead product, the CRH O'Regan System, is a single use, disposable, hemorrhoid treatment that is safe and highly effective in treating hemorrhoid grades I - IV.  The O'Regan System is rapidly emerging as the standard of care with gastroenterologists who treat hemorrhoids. In addition to the product, CRH Medical delivers clinical, marketing and operational support directly to its partner physicians. CRH utilizes its web-based platform to connect doctors with patients as well as educating its ever increasing install base of physicians.

Forward looking statements:
The information in this news release contains so-called "forward-looking" statements. These include statements regarding CRH Medical's expectations and plans relating to its business, statements about CRH Medical's expectations, beliefs, intentions or strategies for the future, which may be indicated by words or phrases such as "anticipate", "expect", "intend", "plan", "will", "we believe", "CRH Medical believes", "management believes", and similar language. All forward-looking statements are based on CRH Medical's current expectations and are subject to risks and uncertainties and to assumptions made. Assumptions include: (i) that the growth of CRH's product sales will continue in a consistent manner; (ii) CRH's costs will not escalate significantly; and (iii) CRH does not incur any extraordinary costs.

Important risk factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include: (i) we may not continue to attract Gastroenterologists and other licensed providers to purchase and use the CRH O'Regan System; (ii) the policies of health insurance carriers in the United States may affect the amount of revenue the Company receives; (iii) changes in United States federal or state laws, rules, and regulations; (iv) our senior management has been key to our growth, and we may be adversely affected if we lose any member of our senior management; (v) Our Clinical Sales Representatives may not be able to increase adoption of the CRH O'Regan System; (vi) economic dependence on suppliers and our contract manufacturer; (vii) changes in the industry and the economy may affect the Company's business; (viii) evolving regulation of corporate governance and public disclosure may result in additional corporate expenses; (ix) we may be subject to competition and technological risk which may impact the price and amount of product we can sell; * we may be subject to product liability which may adversely affect our operations; (xi) we may need to raise additional capital to fund future operations; (xii) our business may be impacted by health care reform in the United States; (xiii) we may not have the expertise required to expand internationally. As a single product company, any adverse event directly or indirectly related to the CRH O'Regan System will have a material impact on the Company's financial performance. CRH Medical bases its forward-looking statements on information currently available to it, and assumes no obligation to update them, except as required by law.

SOURCE: CRH Medical Corporation

Edward Wright, Chief Executive Officer
CRH Medical Corporation
604.633.1440 x1008
[email protected]

or

Adam Peeler, Media and Investor Relations
TMX Equicom
416.815.0700 x 225
[email protected]